The linked FDA PMA records name W. L. Gore & Associates, Inc. as applicant for the balloon-expandable covered stent under P160021 and its supplement. The PMA collection contains two approval entries. A separate enforcement entry describes a short wire biliary endoprosthesis and a Class II recall; it has its own product and recalling-firm fields. These counts describe the linked record sample, rather than the company’s complete portfolio or safety record. [1][2][3]

The VBX endoprosthesis and its original approval

P160021 covers the GORE VIABAHN VBX Balloon Expandable Endoprosthesis, classified as an iliac covered stent, arterial, under product code PRL with a cardiovascular advisory committee. The original approval, decided 27 January 2017, describes an indication for de novo or restenotic lesions in iliac arteries with reference vessel diameters of 5 mm to 13 mm and lesion lengths up to 110 mm, including lesions at the aortic bifurcation. The application was received 5 July 2016 and carries docket number 16M-0560. [2][6]

Supplement S051 and the FEVAR/BEVAR labeling change

Supplement S051 was received 6 February 2026 and approved 8 October 2026 as a Panel Track labeling change to indications, instructions, shelf life or tradename. Its approval statement describes expanding the indications to include use as a bridging stent to maintain visceral artery perfusion in fenestrated and branched endovascular aortic aneurysm repair, abbreviated FEVAR and BEVAR. The FDA PMA page for P160021 lists S051 among the application's supplements and notes that the device description or indication may have changed through supplements. [1][5][9]

Gore Medical's product page states that the VBX Stent Graft is now FDA approved for FEVAR and BEVAR and describes it as the first and only FDA-approved bridging stent, with a reference to branches of 6–8 mm diameter at least 10 mm in length. The same page labels the device MR Conditional and directs readers to the Instructions for Use and MRI safety information. A Gore Medical press release headline announces FDA approval of the device for expanded use in FEVAR and BEVAR. [4][8][10]

The VIABIL biliary endoprosthesis recall

Recall Z-0158-2027, classified Class II and marked Ongoing, concerns the GORE VIABIL Short Wire Biliary Endoprosthesis, models VSWVH0808 and VSWVN1006, which the record describes as a flexible, self-expanding endoprosthesis intended to maintain patency of a possibly obstructed common bile duct. The stated reason is the potential for devices to be mislabeled with an incorrect length. The firm initiated the recall voluntarily, with a recall initiation date of 3 September 2026, a center classification date of 14 October 2026 and a report date of 21 October 2026; the record lists 32 units and nationwide distribution in Georgia and Rhode Island. [3]

How to read the supplied counts

The portfolio snapshot reports two linked records, both under the PMA pathway and both with approval decisions, and the record sample contains exactly those two entries: P160021/S051 and P160021. The sample decision counts therefore match the full collection at two approvals, and neither figure should be read as a measure of the company's entire portfolio or of post-market safety performance. The recall record sits outside those PMA counts. [1][2][3]